Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $13.45

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $14.85.

A number of research analysts recently weighed in on HIMS shares. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. Truist Financial raised their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Piper Sandler raised their target price on shares of Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Tuesday, February 27th. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Wednesday, February 28th. Finally, Guggenheim lifted their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th.

Hims & Hers Health Stock Down 4.0 %

Shares of NYSE:HIMS opened at $12.69 on Wednesday. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $17.16. The company’s fifty day simple moving average is $13.36 and its 200 day simple moving average is $9.77. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -115.36 and a beta of 0.91.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same period last year, the business posted ($0.05) earnings per share. The firm’s quarterly revenue was up 47.4% on a year-over-year basis. Research analysts expect that Hims & Hers Health will post 0.1 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the transaction, the insider now owns 154,345 shares in the company, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 673,335 shares of company stock worth $8,452,208. 31.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Graham Capital Management L.P. increased its stake in shares of Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after purchasing an additional 96,277 shares during the last quarter. Swiss National Bank raised its stake in Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after acquiring an additional 26,100 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after acquiring an additional 428,671 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after acquiring an additional 58,288 shares during the last quarter. Finally, Must Asset Management Inc. acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $1,596,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.